Eicosanoids and Hypertension PharmacologyPharmacological Receptor Mechanisms and EffectsEnzyme function and inhibition

L. Al-Wahaibi, Olivier Blacque, E. R. Tiekink, Ali A. El-Emam

2026.5.12ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES

DOI: 10.1515/ncrs-2026-0106

Abstract

<jats:p> C <jats:sub>15</jats:sub> H <jats:sub>23</jats:sub> N <jats:sub>3</jats:sub> S, orthorhombic, <jats:italic>Pbca</jats:italic> (no. 61), <jats:italic>a</jats:italic>  = 10.0075(1) Å, <jats:italic>b</jats:italic>  = 11.8795(1) Å, <jats:italic>c</jats:italic>  = 23.8519(2) Å, <jats:italic>V</jats:italic>  = 2835.61(4) Å <jats:sup>3</jats:sup> , <jats:italic>Z</jats:italic>  = 8, <jats:italic>R</jats:italic> <jats:sub> <jats:italic>gt</jats:italic> </jats:sub> ( <jats:italic>F</jats:italic> ) = 0.0321, <jats:italic>wR</jats:italic> <jats:sub> <jats:italic>ref</jats:italic> </jats:sub> ( <jats:italic>F</jats:italic> <jats:sup>2</jats:sup> ) = 0.0932, <jats:italic>T</jats:italic>  = 160 K. </jats:p>

Citation format

AL-WAHAIBI, L., et al. Improved synthesis and crystal structure of 3-(adamantan-1-yl)-5-(ethylsulfanyl)-4-methyl-4 h -1,2,4-triazole, c 15 h 23 n 3 s. ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES, 2026.